T2005010
Triflusal impurity B
European Pharmacopoeia (EP) Reference Standard
Sinónimos:
2-Hydroxy-4-(trifluoromethyl)benzoic acid, 4-(Trifluoromethyl)salicylic acid
Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
About This Item
Productos recomendados
grado
pharmaceutical primary standard
familia API
triflusal
fabricante / nombre comercial
EDQM
aplicaciones
pharmaceutical (small molecule)
formato
neat
temp. de almacenamiento
2-8°C
InChI
1S/C8H5F3O3/c9-8(10,11)4-1-2-5(7(13)14)6(12)3-4/h1-3,12H,(H,13,14)
Clave InChI
XMLFPUBZFSJWCN-UHFFFAOYSA-N
Descripción general
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Aplicación
Triflusal impurity B EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Envase
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Otras notas
Sales restrictions may apply.
Choose from one of the most recent versions:
Certificados de análisis (COA)
Sorry, we don't have COAs for this product available online at this time.
If you need assistance, please contact Atención al cliente
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Naunyn-Schmiedeberg's archives of pharmacology, 371(1), 81-88 (2004-12-17)
Triflusal is a fluorinated derivative of acetylsalicylic acid (ASA) with demonstrated antithrombotic activity. Recently, evidence for a neuroprotective effect has been obtained. The aim of this study was to compare the neuroprotective effects of the main metabolite of triflusal (2-hydroxy-4-trifluoromethylbenzoic
Journal of pharmaceutical and biomedical analysis, 46(3), 456-462 (2007-12-21)
This study describes the development and evaluation of an analytical method for the characterization of triflusal (2-acetoxy-4-(trifluoromethyl) benzoic acid) dispersed in sustained delivery systems prepared using supercritical fluid impregnation technology. Characterization assays comprised the determination of the percentage of triflusal
The Journal of urology, 166(5), 1962-1968 (2001-10-05)
We examined the effects of intravenous administration of the 2 nuclear factor-kappaB inhibitors aspirin and 2-hydroxy-4-trifluoromethylbenzoic acid (HTB) on bladder filling and voiding in anesthetized and conscious rats. Disappearance of isovolumic bladder contractions after intravenous administration of different doses of
Molecular pharmacology, 55(4), 753-760 (1999-04-01)
The therapeutic potential of drugs that block the induction of cyclooxygenase-2 has been emphasized. When two 4-trifluoromethyl salicylate derivatives [2-acetoxy-4-trifluoromethyl-benzoic acid (triflusal) and its deacetylated metabolite 2-hydroxy-4-trifluoromethylbenzoic acid (HTB)] were compared with aspirin and sodium salicylate as cyclooxygenase-2 (COX-2) inhibitors
Photochemistry and photobiology, 73(5), 463-468 (2001-05-23)
Triflusal is a platelet antiaggregant drug with photoallergic side effects. However, it is considered a prodrug since it is metabolized to 2-hydroxy-4-trifluoromethylbenzoic acid (HTB)--the pharmacologically active form. HTB was found to be photolabile under various conditions. Its major photodegradation pathway
Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.
Póngase en contacto con el Servicio técnico